Gene Transduction Therapy in Neurodegenerative Disorders
Gene Transduction Therapy in Neurodegenerative Disorders
Induction of axonal regeneration in neurodegenerative disease utilizing viral transduction.
New York, NY, United States
Overview Comments Tagged publications

Background 

Induction of axonal regeneration in neurodegenerative disease utilizing viral transduction

Neurodegenerative conditions such as Parkinson’s Disease, Huntington’s Disease, and Alzheimer’s Disease are devastating neurological diseases which have a high rate of prevalence and effect millions of people worldwide. They are associated with significant and progressive decline in cognitive and motor function secondary to neurodegeneration. Current therapies for such diseases are unable to halt or reverse this associated neurodegeneration and instead focus on neurotransmitter signaling, as in the case of L-Dopa in Parkinson’s Disease. In addition to many adverse effects of these therapies, including dyskinesias and cognitive impairment, deterioration of neuronal function continues to progress, and functional deficits are not repaired. In contrast, this technology seeks to promote regeneration of neuronal axons, thereby reversing deficits of motor and cognitive function. Regeneration of damaged neurons presents a viable therapeutic method, restoring function by promoting cell growth.

Constitutively active p70S6K induces axonal regeneration within cells damaged in neurodegenerative disorders.

The p70S6K gene has been discovered to induce axonal growth when in a constitutively active state. In order to simulate Parkinson’s disease in a mouse model, the Substantia Nigra (SN) was lesioned. Constitutively active p70S6K was introduced into the SN utilizing viral vector induction three weeks after lesioning. These mice showed significant axonal regeneration in this area 12 weeks following introduction of the constitutively active p70S6k gene. 

Applications • Treatment of neurodegenerative disorders such as Parkinson’s, Alzheimer’s, and Huntington’s disease • Potential for axonal regeneration in ischemic, infectious, or traumatic neuron damage

Advantages • Stimulates direct regeneration of the axons of damaged neurons • Avoids potential adverse effects of exogenous neurotransmitter delivery

Related Publications: • Kim SR, Chen X, Oo TF, Kareva T, Wang C, During M, Kholodilov N, Burke RE. Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. Annals of Neurology, Volume 70, Issue 1, 2011: pp 110-120.

• Burke RE. Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacology and Therapeutics. Volume 114, Issue 3, 2007: pp 261-277.

• Kim SR, Kareva T, Yarygina O, Kholodilov N, Burke RE. AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon re-growth. Molecular Therapy, 2012, 20:275-286. (PMCID: PMC3277224).

Lead Inventor:  Robert Burke, M.D.


No comments.
No tagged publications.

Similar innovations

Back
or
Back
Back
or
Back
Back
or
Back
  • Gene therapy for inflammatory and autoimmune diseases
  • This technology comprises inhibitors of antibody production, including IgG, IgA and IgE. These peptide inhibitors are derived from naturally occurring mutations in the CRAF1 (TRAF-3) gene and they specifically inhibit CD40 mediated intracellular signaling. As the CD40-mediated signaling pathway is necessary for B-cell proliferation and antibody production, inhibitors of this pathway act as highly specific and effective immunosuppressants.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Stanford University
Back
or
Back
  • Parkinson's and Huntington's Treatment
  • This technology is an antisense oligonucleotide to the protein Nedd2. Nedd2 is an aspartase expressed by neuronal cells and plays a crucial role in apoptosis. When neurons are deprived of cytokines such as nerve growth factor (NGF), Nedd2 expression is upregulated as part of the apoptotic pathway. This technology is an antisense oligonucleotide (ANedd) capable of blocking expression of Nedd2, thereby inhibiting apoptosis.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Stanford University
← Previous Next → 1 2 3 4 Last
Showing 1-4 from 389

Send Us a Message